Diaceutics (AIM:DXRX) has launched a new study with the Precision Cancer Consortium (PCC) to evaluate how consistently next-generation sequencing (NGS) panels detect genetic variants in routine clinical practice.
The AIM-listed group, which supplies technology and data solutions to the pharma and biotech industry, said the study will assess up to 20 NGS assays used in US laboratories against known reference profiles in synthetic samples.
"As the number and complexity of NGS panels continue to grow, it is increasingly important that laboratories, diagnostics companies, and the wider precision oncology community work together to better understand testing variability", said Susanne Munksted, Diaceutics' chief precision medicine officer.
The initiative builds on Diaceutics' earlier Clinical Practice Gaps in Precision Medicine research, which found improvements in biomarker testing performance alongside growing complexity in the diagnostics landscape.
NGS testing has become central to identifying patients eligible for targeted cancer therapies, making variability between panels and platforms a live concern for the industry.
The companies are inviting laboratories and diagnostics firms to take part, with the aim of generating evidence for future scientific publications and industry discussions on testing quality and transparency.
News Intelligence what this means for the company
Diaceutics has launched a study with the Precision Cancer Consortium to assess consistency in variant detection across up to 20 NGS panels used in US clinical labs, testing them against reference profiles. The initiative addresses a real operational pain point—variability in NGS testing affects which patients qualify for targeted cancer therapies—and positions Diaceutics' diagnostic intelligence platform as a bridge between labs, diagnostics firms, and pharma on testing quality, but the study itself generates no immediate revenue and its timeline depends on third-party participation.
The study reinforces Diaceutics' positioning in precision oncology diagnostics and may yield publications and industry credibility that support future PMx partnerships and customer retention, but it is a research initiative rather than a commercial contract. Against a contracted order book of £43.7m at end-H1 2026, this announcement adds strategic visibility without near-term financial impact.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
